Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 12:03 PM
Ignite Modification Date: 2025-12-24 @ 12:03 PM
NCT ID: NCT04741061
Eligibility Criteria: Inclusion Criteria: 1. Agree to sign the study informed consent form (ICF) before performing any study specific procedure 2. Adults ≥ 18 years old 3. Negative COVID-19 PCR test result at the screening visit and negative immunochromatographic SARS-CoV-2 antigen rapid-test result at the enrolment 4. Consent for using effective methods of contraception during the study 5. No evidence of vaccine-induced reactions or complications after receiving immunobiological products in medical history 6. No acute infectious and/or respiratory diseases within at least 14 days before the enrolment Exclusion Criteria: 1. Any previous vaccination/immunization (within 30 days before the enrollment) and any planned vaccination within 30 days after enrollment 2. Any previous or planning COVID-19 vaccination with any other Regulatory approved vaccine 3. Positive SARS-CoV-2 screening result obtained by PCR (at screening) 4. Administration of steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment 5. Pregnancy or lactation 6. Acute coronary syndrome or stroke suffered less than one year before study enrollment 7. Tuberculosis, chronic systemic infections associated with Immunocompromised subjects in medical history 8. History of severe allergic reaction to drug or vaccine (anaphylactic shock, Quincke's edema, and other life-threatening allergic reactions), acute exacerbation of allergic diseases on screening and vaccination day 9. Chronic autoimmune disease and system collagenases in medical history 10. Organ transplantation and immunosuppressive therapy 11. Immunosuppressive therapy and corticosteroid system therapy within 3 months before the enrollment 12. Subjects with malignant neoplasms within 5 years before the enrollment 13. Splenectomy in the past medical history 14. Neutropenia (absolute neutrophil count \<1,000 mm3 agranulocytosis, significant blood loss, severe anemia (hemoglobin \<80 g/L), immunodeficient disease in the medical history within 6 months before the enrollment 15. The active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis B, or C 16. Acute Kidney injury or dialysis 17. Anorexia or dysnutrition 18. Tattoos at the injection site (deltoid muscle area), which in the medical opinion of the investigator does not allow assessing the local response to the vaccine/placebo 19. Alcohol or Drug abuse in medical history 20. Participation in other interventional clinical trial within the previous 90 days prior to vaccination and over duration of the trial 21. Any other condition that the investigator considers as a barrier to the trial completion as per the protocol
Healthy Volunteers: True
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 111 Years
Study: NCT04741061
Study Brief:
Protocol Section: NCT04741061